Results 211 to 220 of about 7,679,537 (277)

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang   +36 more
wiley   +1 more source

Biomimetic Nanomedicine for Aging‐Impaired Bone Regeneration: From Microenvironmental Dysfunction to Precision Therapeutics

open access: yesAdvanced NanoBiomed Research, EarlyView.
Aging disrupts the cellular, immune, vascular, and neural processes required for bone regeneration. This review connects these pathological barriers with biomimetic nanomedicine design, highlighting strategies for cellular rejuvenation, immune modulation, vascular regeneration, and neuro–bone coupling.
Zeyu Wang   +12 more
wiley   +1 more source

Beyond Formate Trapping: A Mechanistic Framework for Homogeneous CO2‐to‐Methanol Conversion With First‐Row Transition Metals

open access: yesAngewandte Chemie, EarlyView.
This review shows that converting CO2 into methanol with catalysts based on abundant first‐row metals requires more than overcoming formate formation. Success depends on balancing hydrogen activation, intermediate reactivity, product release, and catalyst stability.
Elise Boudry, Christophe M. Thomas
wiley   +1 more source

Impact of Market Authorization Holder (MAH) system on pharmaceutical innovation in China. [PDF]

open access: yesJ Pharm Policy Pract
Zhai S   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy